Zymeworks is converting Ziihera clinical validation and the Theravance acquisition into a royalty engine, with an August 25 PDUFA as the decisive catalyst.
Overview
Zymeworks is restructuring into a royalty-focused biopharmaceutical company built around partnered Ziihera royalties, YUPELRI cash flows and a selectively funded multispecific/ADC pipeline. Ziihera’s HERIZON-GEA-01 data showed median PFS of 12.4 months versus 8.1 months for trastuzumab chemotherapy, with HR 0.63 and p<0.0001, supporting a potential first-line GEA standard of care across PD-L1-positive and negative patients. **The key near-term catalyst is the August 25, 2026 FDA PDUFA date**, which could trigger a $250.0 million milestone and up to $190.0 million of subsequent global milestones. The Theravance acquisition adds YUPELRI, the only approved once-daily nebulized LAMA, approximately $60.0-$70.0 million of recurring cash flow, a potential $100.0 million TRELEGY milestone in Q1 2027 and $2.5 billion of Irish tax attributes. Q2 revenue fell 90.6% to $4.59 million and net loss was $45.02 million, but the market largely looked through the milestone-driven volatility. The DCF yields $22.44 intrinsic value versus a $23.54 share price, while the probability-weighted 2031 target is $43.89. **The investment is therefore a catalyst-driven, execution-dependent royalty-compounding story rather than a near-term earnings play.**